Plus   Neg

Royalty Pharma Prices IPO At High End Of Range

Royalty Pharma plc announced the pricing of initial public offering of 77.68 million shares of Class A ordinary shares at $28 per share, the high end of the expected range of $25 to $28. The offering is expected to close on June 18, 2020.

The size of the IPO was increased from the previously announced 70 million Class A ordinary shares.

Royalty Pharma is offering 60 million Class A ordinary shares and the selling shareholders are offering 17.68 million Class A ordinary shares.

The company grants underwriters a 30-day option to purchase up to an additional 11.65 million Class A ordinary shares.

Royalty Pharma Class A ordinary shares are expected to begin trading on the Nasdaq Global Select Market on June 16, 2020 under the ticker symbol "RPRX."

J.P. Morgan, Morgan Stanley, BofA Securities, Goldman Sachs & Co. LLC, Citigroup and UBS Investment Bank are acting as joint lead book-running managers and as representatives of the underwriters for the offering.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Pfizer said Friday it reached a multi-year deal with Gilead Sciences to manufacture and supply Gilead's investigational antiviral remdesivir for COVID-19 patients. Ferring Pharmaceuticals US is recalling various nasal sprays citing superpotency or amounts of desmopressin higher than specified, the U.S. Food and Drug Administration announced in a statement. The recall involves all lots on the market of DDAVP Nasal Spray 10 mcg/0.1mL, Desmopressin Acetate Nasal Spray 10 mcg/0.1mL, and STIMATE Nasal Spray 1.5 mg/mL. U.S. President Donald Trump has issued executive orders to ban Chinese mobile application TikTok as well as WeChat, citing a threat to national security and its economy. China's ByteDance Ltd. owns TikTok, a video-sharing mobile app, while Tencent Holdings Ltd. owns WeChat, a messaging, social media, and electronic payment app.
Follow RTT